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ABSTRACT 
 
We have previously shown that ablation of either the Phospho1 or Alpl gene, encoding 
PHOSPHO1 and tissue-nonspecific alkaline phosphatase (TNAP) respectively, lead to 
hyperosteoidosis but that their chondrocyte- and osteoblast-derived matrix vesicles 
(MVs) are able to initiate mineralization. In contrast, the double ablation of Phospho1 
and Alpl completely abolishes initiation and progression of skeletal mineralization. We 
argued that MVs initiate mineralization by a dual mechanism: PHOSPHO1-mediated 
intravesicular generation of Pi and phosphate transporter-mediated influx of Pi generated 
perivesicularly. To test this hypothesis, we generated mice with the col2a1-driven cre-
mediated ablation of Pit1 alone or in combination with a Phospho1 gene deletion. 
Pit1col2/col2 mice did not show any major phenotypic abnormalities, while severe skeletal 
deformities were observed in the [Phospho1-/-; Pit1col2/col2] double knockout mice that 
were more pronounced than those observed in the Phospho1-/- mice. Histological analysis 
of 15 day old [Phospho1-/-; Pit1col2/col2] bones showed growth plate abnormalities with a 
shorter hypertrophic chondrocyte zone and extensive hyperosteoidosis. The [Phospho1-/-; 
Pit1col2/col2] skeleton displayed significantly decreases in BV/TV%, trabecular number and 
bone mineral density (BMD) with increased trabecular separation for both tibia and 
femur compared to Phospho1-/- mice. Three-point bending analysis also showed that 
[Phospho1-/-; Pit1col2/col2] bones take longer deflection to break and show decreased 
maximum load and increased post-yield deflection suggesting the elastic nature of these 
bones. By atomic force microscopy (AFM) we found that approximately 70% of 
[Phospho1-/-; Pit1col2/col2] MVs were empty, in comparison to about 20-30 % empty MVs 
for the WT, Phospho1-/- and  Pit1col2/col2 MVs. We also found a significant decrease in the 
number of MVs produced by both Phospho1-/- and [Phospho1-/-; Pit1col2/col2] chondrocytes. 
These data proves the involvement of PiT-1 function in the initiation of skeletal 
mineralization and it provides compelling evidence that PHOSPHO1 mediates MV 
biogenesis.  
  
INTRODUCTION 
Mineralization of cartilage and bone occurs by a series of physicochemical and 
biochemical processes that together facilitate the deposition of hydroxyapatite in specific 
areas of the extracellular matrix (ECM). Tissue-nonspecific alkaline phosphatase (TNAP) 
plays a crucial role in restricting the concentration of the mineralization inhibitor 
inorganic pyrophosphate (PPi) to maintain a Pi/PPi ratio permissive for normal 
propagation of mineral in the extracellular matrix (Moss et al., 1967; Majeska et al., 
1975; Johnson et al., 2000; Hessle et al., 2002; Murshed et al., 2005; Yadav et al., 2011; 
Millán, 2012; McKee et al., 2013). Alpl-/- mice chondrocyte and osteoblast-derived matrix 
vesicles (MVs) however are still able to initiate mineralization (Anderson et al., 1997, 
2004), indicating that other enzymes or mechanisms are involved in the intravesicular 
initiation of mineralization. Subsequently, we showed that PHOSPHO1, an enzyme that 
uses phosphocholine and phosphoethanolamine to concentrate Pi inside MVs, is also 
required for proper bone mineralization (Roberts et al., 2007; Huesa et al., 2011; Yadav 
et al., 2011; McKee et al., 2013), as the lack of PHOSPHO1 (Phospho1-/- mice) also 
leads to skeletal and dental hypomineralization. Importantly, the [Alpl-/-; Phospho1-/-] 
double knockout mice are embryonic lethal and the E16.5 embryos show complete 
absence of skeletal mineralization and MVs devoid of mineral (Yadav et al., 2011). We 
hypothesized that MV-mediated initiation of mineralization results from a dual 
mechanism, i.e. PHOSPHO1-mediated intra-vesicular production and transporter-
mediated influx of Pi. Two related type III Na/Pi co-transporters, PiT-1/Glvr1 and PiT-
2/Ram, are both expressed by chondrocytes and osteoblasts, but literature reports that 
PiT-1 is the major mediator of Pi influx in these cell types (Nielsen et al., 2001; Yoshiko 
et al., 2007; Polewski et al., 2010). Thus, to test this hypothesis we generated mice with a 
conditional ablation of PiT-1 gene (Slc20a1, here referred to as Pit1) alone or in the 
Phospho1-/- background. Our data proves the involvement of PiT-1 function in the 
initiation of endochondral ossification and also points to PHOSPHO1 as an enzyme 
controlling MV biogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
Mice 
Phospho1-R74X null mutant (Phospho1-/-) mice were generated as described (Yadav et 
al., 2011). The generation and characterization of the Pit1flox/flox mice was reported earlier 
(Beck et al., 2010). To generate mice lacking both PHOSPHO1 and PiT-11, Phospho1-/- 
mice were crossed to Pit1flox/flox mice and double heterozygote mice were used to generate 
[Phospho1-/-; Pit1flox/flox] double mutant mice. These mice were then bred with Col2a1-cre 
mice to generate [Pit1flox/flox; Col2a1-cre], here named Pit1col2/col2 and  [Phospho1-/-; 
Pit1col2/col2] mice. Phospho1-/- genotypes were determined using genomic DNA, PCR and 
restriction digestion by BsrD1 restriction enzyme (Yadav et al., 2011). Pit1col2/col2 and  
[Phospho1-/-; Pit1col2/col2] mice were genotyped by PCR. The primer sequences for 
genotyping were: Phospho1: F 5’ TCCTCCTCACCTTCGACTTC -3’, R 5’- 
ATGCGGCGGAATAAACTGT -3’, Pit1flox/flox: F 5’ AAGGCATTTGTCAGCCCAGTC-
3’, R 5’ ATCGATCCACTCAGTCTAGTGC-3’ and Col2a1-cre: zndhhc14 F-5’ 
GGCAGGAAAGAGTCCAGGTATG-3’, zndhhc14 R-5’ –
TAAGCACTGACAGATGACCTGC-3’, Col2a1-cre F-5’ 
TTAGCCTGGATAGAGCAACCGC-3’. 
 
Tissue and plasma collection and histological studies  
Mice were anesthetized by intraperitoneal injection of Avertin and blood was collected 
by cardiac puncture. Whole-body, long bones and spine radiographic images were taken 
using an MX20 Specimen Radiograph System (Faxitron X-ray Corporation, Chicago, IL, 
USA) at 1 month of age. The lumbar spines, tibias, and femurs of 15-days-old mice were 
fixed in PBS containing 4% (vol/vol) paraformaldehyde. Paraffin or plastic sections were 
stained with Von Kossa/Van Gieson stain using standard procedures (Murshed et al., 
2005; Millan et al., 2008 and Narisawa et al., 2001). Von Kossa/Van Gieson–stained 
slides were used for quantification of osteoid volume using the Bioquant Osteo Software 
(Bioquant Osteoanalysis Co., Nashville, TN, USA.  
 
For PiT-1 immunohistochemistry, bone tissues were decalcified with 0.125 M 
EDTA/10% formalin in H2O (pH 7.2) for five days after fixation, and processed for 
paraffin sectioning. Immunostaining was performed using a standard avidin-biotin 
complex protocol using the Vectastatin ABC kit (Vector laboratories Inc, Burlingame, 
CA). Rabbit anti-mouse OPN antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
USA) was used for detection of PiT-1.  
 
Pit1 gene expression  
Primary chondrocytes from WT and Pit1col2/col2 mice were isolated from the knee joint 
growth plates of 5 day-old pups by collagenase digestion, as described previously (Yadav 
et al., 2011). RNA was extracted using RNAeasy Pus Kit (Qiagen, Valencia, CA, USA). 
Specific RNA transcript (mRNA) for Pit1 was quantified by real-time PCR using dual-
labeled hydrolysis probes (FAM-TAMRA). Pit1 primers and probe sequences are as 
follows: F-5’GGCTCAGGTGTAGTGACCCT3’, R-5’ 
CACATCTATCAAGCCGTTCC3’ and FAM-TAMRA Probe-
5’CGAAACTGTGGGCTCCGCC3’. 
 
Biochemical assays 
Blood was collected by cardiac puncture into lithium heparin tubes and plasma was 
collected by centrifugation at 5000 rpm for 10min. Alkaline phosphatase activity in 
plasma was measured using a previously reported method (Millán et al., 2008). PPi levels 
were measured using activated charcoal and 3H method as we previously reported 
(Mcguire et al., 1980; Yadav et al, 2011). Calcium levels were measured using the 
cresolphthalein complexone liquicolor test kit (Stanbio, Boerne, Tx, USA) according to 
the manufacturer’s protocol. 
 
Micro–computed tomography (µCT) 
Mice were euthanized at 1 month of age, the tibias and femurs dissected and fixed in 4% 
paraformaldehyde. Samples were imaged on a µCT scanner (Skyscan 1076, Kontich, 
Belgium). Samples were wrapped in tissue paper that was moistened with phosphate 
buffered saline (PBS), and scanned at 9µm voxel size, applying an electrical potential of 
50 kVp and current of 200uA, using a 0.5mm aluminum filter. Mineral density was 
determined by calibration of images against 2mm diameter hydroxyapatite (HA) rods 
(0.25 and 0.75 gHA/cm3). Additionally, a beam hardening correction algorithm was 
applied prior to image reconstruction.  
 
To visualize and determine bone histomorphometric parameters, the software, 
Dataviewer, CTAn, CTVol and CTVox (all Skyscan, Kontich, Belgium) was used. 
Cortical bone analysis was performed on the femur and tibia midshafts. The volumes of 
interest were selected in reference to an identified landmark1. Since all animals were 1 
month of age, the volumes of interest were (1) 3600-4500 µm proximal to the distal 
femur growth plate and (2) 3600-4500 µm distal to the tibia proximal growth plate. The 
cortical bone in this region was selected by automatic contouring of the periosteal tissue 
excluding the marrow cavity. A global threshold was used to identify cortical bone and 
an erosion of one pixel was performed to eliminate partial volume effects. From these 
regions of femoral and tibial cortical bone, the following parameters were determined: 
cross-sectional tissue area (T.Ar), cross-sectional cortical bone area (B.Ar), cortical bone 
area fraction (B.Ar/T.Ar), cross-sectional bone thickness (Cs.Th) and tissue mineral 
density (TMD).  
 
Trabecular bone analysis was performed at the distal femoral metaphysis and proximal 
tibial metaphysis. The regions of interest were (1) 360-2160 µm proximal to the distal 
femoral growth plate, and (2) 360-2160 µm distal to the proximal tibial growth plate. The 
trabecular region was selected by automatic contouring. An adaptive threshold (using the 
mean maximum and minimum pixel intensity values of the surrounding ten pixels) was 
used to identify trabecular bone and an erosion of one pixel was performed to eliminate 
partial volume effects. From these regions of femoral and tibial trabecular bone the 
following parameters were determined: tissue volume (TV), trabecular bone volume 
(BV), trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular 
separation (Tb.Sp), trabecular number (Tb.N), structure model index (SMI), trabecular 
pattern factor (Tb.Pf), and bone mineral density (BMD). µCT analyses of the trabecular 
bone was performed on a 2mm section of the right tibial and femoral metaphysis 250 µm 
distal to the growth plate using a Skyscan 1172 instrument (Kontlich, Belgium) set at 60 
kV, 150 µA and at a resolution of 5 µm. The cortical analysis was conducted on a 250 µm 
section 2.25 mm distal of the reference growth plate. The spines were dissected from the 
cervical to the second lumbar vertebrae and the thoracic vertebrae scanned at a resolution 
of 20µm. The images were reconstructed using the Skyscan NRecon program, analyzed 
using Skyscan CTAn and the 3 dimensional (3D) models visualized in CTvol software 
(Yadav et al., 2011). 
3-point bending for the determination of bone stiffness and breaking strength  
An Instron 3342 materials testing machine (Instron, Norwood, MA, USA) fitted with a 2 
kN load cell was used to determine bone stiffness and breaking strength (Aspden, 2003). 
The span was fixed at 5.12 mm for femurs. The cross-head was lowered at 1 mm/min and 
data were recorded after every 0.2 N change in load and every 0.1 mm change in 
deflection. Each bone was tested to fracture. Failure and fracture points were identified 
from the load-extension curve as the point of maximum load and where the load rapidly 
decreased to zero, respectively. The maximum stiffness was defined as the maximum 
gradient of the rising portion of this curve, and the yield point, the point at which the 
gradient reduced to 95% of this value. Both values were calculated from a polynomial 
curve fitted to the rising region of the load-extension curve in Mathcad (Mathsoft 
Engineering and Education Inc., Cambridge, MA, USA).  
Atomic force microscopy (AFM) 
A drop (5 µL) of each MV solution in Tris-buffered-saline was spotted on freshly cleaved 
mica substrates (Ted Pella, Redding, CA) and allowed to stand for 5 min. Next, 5 µL of 
glutaraldehyde solution (8% in H2O, Sigma-Aldrich, St. Louis, MO) was dropped onto 
the samples. The substrates were stored inside a desiccators at room temperature for 24 h. 
AFM images of dried samples were recorded in air by means of an 5500 atomic force 
microscope (Agilent Technologies, Santa Clara, CA) equipped with an open-loop probe 
working in non-contact (AAC) mode. Silicon-nitride cantilevers having a nominal 
resonance frequency of ~190 kHz (NanosensorsTM, Neuchatel, Switzerland) were used. 
Tridimensional AFM images were generated by PicoView software (Agilent 
Technologies). 
 
AFM images were used to gather information about the morphology and number of MVs 
in each sample. The cross section of N=100 MVs in each sample was recorded and the 
MVs' diameter was calculated as the peak value in the cross section. The number of MVs 
in each sample was calculated as number of MVs per µm2 by counting the globular 
features in N=20 scan fields (2 × 2 µm). Mean and SD values were obtained through 
Gaussian fit of the value distributions. 
 
Statistical analysis 
All measurements were performed at least in triplicate. Results are expressed as mean ± 
SEM. The data were analyzed using Student’s t test. P values less than 0.05 were 
considered significant. For AFM, statistical differences among samples were calculated 
by non-parametric Mann–Whitney U analysis performed by SPSS Statistics (IBM 
Corporation, Armonk, NY). 
  
RESULTS 
Skeletal phenotype of [Phospho1-/-; Pit1col2/col2] mice 
Immunohistochemistry demonstrated reduced PiT-1 expression in the proliferative and 
hypertrophic chondrocyte area of the knee joint section of the growth plate of 1-month-
old Pit1col2/col2 mice compared to WT mice (Fig. 1A). There was visible residual PiT1 
expression in these cells that was estimated to be 35% by qPCR (Fig. 1B). The Pit1col2/col2 
mice were comparable to WT mice in size but the [Phospho1-/-; Pit1col2/col2] mice were 
even smaller than age-matched Phospho1-/- mice, which we had shown to be runted 
(Yadav et al., 2011) (Fig. 1C). The [Phospho1-/-; Pit1col2/col2] skeletons showed 
exacerbated abnormalities compared to the Phospho1-/- mice, including multiple fractures 
and callus formation in the ribs, increased bowing of the long bones and increased 
prevalence of fractures in these bones (Fig. 2). 
 
Histology evidenced shortened growth plate in the [Phospho1-/-; Pit1col2/col2] bones (Fig. 
3A). Histomorphometric analyses in 15-days-old mice confirmed the osteomalacia 
previously reported in 10-days-old and 1-month-old Phospho1-/- mice (Yadav et al., 2011, 
2014) (Fig. 3A, arrows), and showed worsening of this phenotype in the tibias of 
[Phospho1-/-; Pit1col2/col2] mice (BV/TV%, WT = 43.16 ± 2.924, Phospho1-/- = 24.87 ± 
1.055, Pit1col2/col2 = 40.04 ± 3.23, [Phospho1-/-; Pit1col2/col2] =17.85 ± 1.51, n=3; WT vs 
[Phospho1-/-; Pit1col2/col2], p=0.002; Phospho1-/- vs [Phospho1-/-; Pit1col2/col2], p=0.02; 
Pit1col2/col2 vs [Phospho1-/-; Pit1col2/col2], p=0.003; WT vs [Phospho1-/-; Pit1col2/col2], p=0.5) 
and (OV/BV%, WT= 0.0017 ± 9.405e-005, Phospho1-/- = 9.87 ± 3.18, Pit1col2/col2 = 
0.0018 ± 0.00010, [Phospho1-/-; Pit1col2/col2] =24.80 ± 1.82, n=3; WT vs [Phospho1-/-; 
Pit1col2/col2], p=0.0002; Phospho1-/- vs [Phospho1-/-; Pit1col2/col2], p=0.04; Pit1col2/col2 vs 
[Phospho1-/-; Pit1col2/col2], p=0.0002; WT vs [Phospho1-/-; Pit1col2/col2], p=0.75)  (Fig. 2A).  
There was a complete absence of mineralization in the trabecular bone in certain areas 
(arrows). The secondary ossification centers also show increased amount of osteoid in 
these mice. The vertebral sections also showed the presence of widespread 
hyperosteoidosis in the Phospho1-/- mice (Fig. 3B, arrows), which further increased in 
[Phospho1-/-; Pit1col2/col2] mice (BV/TV%, WT= 33.22 ± 2.01, Phospho1-/- = 24.08 ± 1.35, 
Pit1col2/col2 =31.96±0.61, [Phospho1-/-; Pit1col2/col2] =18.87±0.64, n=3; WT vs [Phospho1-/-; 
Pit1col2/col2], p=0.002; Phospho1-/- vs [Phospho1-/-; Pit1col2/col2], p=0.02; Pit1col2/col2 vs 
[Phospho1-/-; Pit1col2/col2], p=0.0001; WT vs [Phospho1-/-; Pit1col2/col2], p=0.58) and 
(OV/BV%, WT= 0.0028 ± 0.00017, Phospho1-/- = 3.96 ± 1.16, Pit1col2/col2 = 0.0027 ± 
0.00011, [Phospho1-/-; Pit1col2/col2] =9.82 ± 0.99, n=3; WT vs [Phospho1-/-; Pit1col2/col2], 
p=0.0006; Phospho1-/- vs [Phospho1-/-; Pit1col2/col2], p=0.02; Pit1col2/col2 vs [Phospho1-/-; 
Pit1col2/col2], p=0.0006; WT vs [Phospho1-/-; Pit1col2/col2], p=0.68)  (Fig. 3B). !μCT analysis concurred with the radiographic and histology data showing enhanced 
bowing of the long bones in both tibia and femur of the [Phospho1-/-; Pit1col2/col2] 
compared to the Phospho1-/- mice (Fig. 4A, B). Trabecular parameters of the femur 
(Table 1) of  [Phospho1-/-; Pit1col2/col2] compared to Phospho1-/- mice showed 
significantly decreased BV/TV% (p=0.003), increased trabecular separation (p= 0.02), 
decreased trabecular number p=0.002) and decreased bone mineral density (p=0.002). 
Similarly for the tibia (Table 2) the [Phospho1-/-; Pit1col2/col2] compared to Phospho1-/- 
mice showed significantly decreased BV/TV% (p=0.003) increased trabecular separation 
(p= 0.002), decreased trabecular number (p=0.001) and decreased bone mineral density 
(p=0.01). Also, the cortical parameters of femur (Table 3) show significantly decreased 
relative bone area (p= 0.01) and cross-sectional area (p= 0.01) in the [Phospho1-/-; 
Pit1col2/col2] compared to Phospho1-/- mice. Similarly, the cortical parameters of femur in 
these mice show significantly decreased relative bone area (p= 0.02), cross-sectional area 
(p= 0.02) and also the tissue mineral density (p=0.03). The Pit1col2/col2 mice also show 
reduced BV/TV%, trabecular number and thickness and increased trabecular separations 
in the femur as compared to the WT mice. Similar results were observed for the tibia 
(Table 4). Three-point bending analysis demonstrated that Pit1col2/col2 femurs break like 
WT but take a little longer deflection to break as compared to the WT mice. However, 
[Phospho1-/-; Pit1col2/col2] bones take even longer deflection and do not break (Fig. 5). 
 
Reduced plasma TNAP activity was observed in 1-month-old [Phospho1-/-; Pit1col2/col2] 
mice compared to WT mice (Fig. 6A). Consistent with the measured TNAP levels we 
measured increased plasma PPi levels in [Phospho1-/-; Pit1col2/col2] compared to WT, 
Pit1col2/col2 and Phospho1-/- mice (Fig. 6B).  
 
Analyses of MVs 
We used atomic force microscopy (AFM) to investigate the morphology (shape and 
diameter) and numbers of isolated MVs. MVs appeared spherical and either individually 
dispersed or connected to ~1 nm-thick chains, which were interpreted as cytoskeleton 
macromolecules (Supplemental Fig. 1). Air-dried MVs were imaged without any coating 
or first coated with glutaraldehyde and then dried before imaging to calculate the number 
of filled vs unfilled MV (Supplemental Fig. 2A, B). The distribution of the height of the 
vesicles was different among samples. WT MVs showed a bi-modal distribution of height 
values with a narrow peak centered at ~ 2.3 nm and a broad one centered at ~7.4 nm, 
respectively (Supplemental Fig. 2C). Similar bi-modal distribution of height values was 
found for Pit1col2/col2 MVs. Phospho1-/- MVs and [Phospho1-/-; Pit1col2/col2] MVs also 
show a bimodal distribution but with much smaller values. For Phospho1-/- the broad 
peak was at 4.8 nm and the narrow peak was at 1.8nm. The [Phospho1-/-; Pit1col2/col2] 
mice show even smaller heights as compared to Phospho1-/-, as the broad peak was at 3.9 
nm and the narrow peak was at 1.9 nm. We interpreted the MVs with a height lower than 
7 nm as unfilled MVs, whereas those with a height greater than 7 nm as filled MVs. Thus, 
we found that WT and Pit1col2/col2 MVs were mostly filled (xx% and xx% of filled MVs, 
respectively), whereas Phospho1-/- MVs and [Phospho1-/-; Pit1col2/col2] MVs were mostly 
unfilled (xx% and xx% of filled MVs, respectively) (Fig. 7A). Additionally, we found 
that empty MVs in the [Phospho1-/-; Pit1col2/col2] preparations were smaller than those in 
the Phospho1-/- samples. We also determined the volume of these MVs (Supplemental 
Fig. 2D) and observed that WT and Pit1col2/col2 MVs have broader volume peaks 
corresponding to 143 x 103 nm3 and 135 x103 nm3. However, the Phospho1-/- MVs had a 
volume peak at 35 x 103 nm3 and the [Phospho1-/-; Pit1col2/col2] MVs had even lesser 
volume of 16 x 103 nm3, in agreement with our interpretation based on the height data 
that these vesicles were mostly unfilled.  Finally, we found that the number of MVs per 
µm2 for the Phospho1-/- and [Phospho1-/-; Pit1col2/col2] samples was significantly lower 
than the number of MVs in the WT and Pit1col2/col2 samples (Fig. 7B). The slight 
difference in number of MVs per µm2 was not statistically significant. These data clearly 
point to a role of PHOSPHO1 in MV biogenesis.  
DISCUSSION 
 
 
 
  
Table 1: Trabecular parameter of the femur. 
 
  
!!
Site%
Tissue%
Volume%
Bone%
Volume%
Rela1ve%
Bone%
Volume%
Trabecular%
Thickness%
Trabecular%
Separa1on%
Trabecula
r%Number%
Structure%
Model%
Index%
Trabecular%
pa>ern%
factor%
Bone%
Mineral%
Density%
!! TV% BV% BV/TV% Tb.Th% Tb.Sp% Tb.N% SMI% Tb.Pf% BMD%
Sample% mm^3% mm^3% %% mm% mm% 1/mm% % 1/mm% g/cm^3%
WT% Femur! 1.80! 0.17! 9.33! 0.04! 0.21! 2.36! 1.97! 27.17! 0.22!
Phospho1'/') Femur! 2.17% 0.14% 6.50% 0.03% 0.21% 1.87% 2.13% 33.75% 0.17%
Pit1)ﬂox/ﬂox;)Col2a1'cre) Femur! 2.57! 0.15! 5.74! 0.03! 0.24! 1.72! 2.18! 35.76! 0.14!
Phospho1'/';)Pit1)ﬂox/ﬂox;)
Col2a1'cre) Femur! 1.56! 0.05! 3.11! 0.03! 0.30! 0.93! 2.44! 43.81! 0.10!
Table 2: Trabecular parameters of the tibia 
 
 
 
  
!!
Site%
Tissue%
Volume%
Bone%
Volume%
Rela1ve%
Bone%
Volume%
Trabecular%
Thickness%
Trabecular%
Separa1on%
Trabecular%
Number%
Structure%
Model%
Index%
Trabecular%
pa>ern%
factor%
Bone%
Mineral%
Density%!!
Sample%
TV% BV% BV/TV% Tb.Th% Tb.Sp% Tb.N% SMI% Tb.Pf% BMD%
mm^3% mm^3% %% mm% mm% 1/mm% % 1/mm% g/cm^3%
WT% Tibia! 1.10! 0.05! 4.57! 0.03! 0.23! 1.53! 2.18! 39.37! 0.17!
Phospho1'/') Tibia! 1.64! 0.07! 4.49! 0.03! 0.22! 1.56! 2.15! 39.63! 0.16!
Pit1)ﬂox/ﬂox;)Col2a1'cre) Tibia! 1.87! 0.07! 3.52! 0.03! 0.26! 1.24! 2.23! 41.52! 0.12!
Phospho1'/';)Pit1)ﬂox/ﬂox;)
Col2a1'cre) Tibia! 1.09! 0.04! 3.30! 0.03! 0.26! 1.10! 2.34! 43.31! 0.11!
Table 3: Cortical parameters of the femur 
 
 
 
  
Sample'
'
Cross,sec.onal'
Tissue'Area'
Cross,sec.onal'
Bone'Area'
Rela.ve'
Bone'Area'
Cross,sec.onal'
thickness'
Tissue'Mineral'
Density'
' T.Ar' B.Ar' B.Ar/T.Ar' Cs.Th' TMD'
Site' mm^2' mm^2' %' mm' g/cm3'
WT' Femur& 1.500& 0.654& 42.95& 0.160& 0.892&
Phospho1'/') Femur& 1.824& 0.732& 40.19& 0.147& 0.866&
Pit1)ﬂox/ﬂox;)Col2a1'cre) Femur& 1.668& 0.651& 38.97& 0.140& 0.904&
Phospho1'/';)Pit1)ﬂox/ﬂox;)Col2a1'cre) Femur& 1.533& 0.478& 30.846& 0.107& 0.846&
Table 4: Cortical parameters of the tibia 
 
  
Sample'
'
Cross,sec.onal'
Tissue'Area'
Cross,sec.onal'
Bone'Area'
Rela.ve'
Bone'Area'
Cross,sec.onal'
thickness'
Tissue'Mineral'
Density'
' T.Ar' B.Ar' B.Ar/T.Ar' Cs.Th' TMD'
Site' mm^2' mm^2' %' mm' g/cm3'
WT' Tibia% 1.496% 0.643% 42.04% 0.158% 1.005%
Phospho1'/') Tibia% 1.609% 0.670% 41.60% 0.150% 0.919%
Pit1)ﬂox/ﬂox;)Col2a1'cre) Tibia% 1.700% 0.610% 35.82% 0.125% 0.927%
Phospho1'/';)Pit1)ﬂox/ﬂox;)Col2a1'cre) Tibia% 1.447% 0.507% 34.666% 0.119% 0.867%
LEGEND TO FIGURES 
 
Fig.1: Phenotypic abnormalities in [Phospho1-/-; Pit1col2/col2] mice. (A) 
Immunohistochemistry using anti-PiT1 antibody on the femur from Phospho1-/- and 
Pit1col2/col2 mice shows reduced PiT-1 expression in the hypertrophic chondrocyte region 
of Pit1col2/col2 mice. B) qRT-PCR showing visible residual Pit1 gene expression (~35%) in 
chondrocytes (C) Phospho1-/- mice are smaller than WT mice and the [Phospho1-/-; 
Pit1col2/col2] mice were even smaller than the Phospho1-/- mice.  
 
Fig. 2: X-ray images. Radiographic images showed worsening of the skeletal 
abnormalities (arrows) in [Phospho1-/-; Pit1col2/col2] mice as compared to the Phospho1-/- 
mice. Arrows show highly bowed long bones and multiple fractures in the spine and 
limbs in [Phospho1-/-; Pit1col2/col2] mice. 
 
Fig. 3: Histomorphometric analyses of tibias (A) and spines (B) of Phospho1-/- and 
[Phospho1-/-; Pit1col2/col2] mice at 15-days of age. Images for WT and Pit1col2/col2 not 
shown. Histograms show comparison between WT, Phospho1-/-, Pit1col2/col2 and 
[Phospho1-/-; Pit1col2/col2] mice for BV/TV% and OV/BV% for tibia (A) and spine (B). 
Von Kossa/van Gieson staining of the tibial section at the knee joint reveals trabecular 
bone surrounded by widespread, extended osteoid in 15-day-old Phospho1-/- mice (arrows 
the areas where the osteoid is present) as compared to the WT mice. The Pit1col2/col2 mice 
appear similar to the WT mice with no osteoid. However, the [Phospho1-/-; Pit1col2/col2] 
mice show even more unmineralized bone in tibia (trabecular bone, secondary 
ossification center) as well as in the spine (vertebrae). 
 
Fig. 4: µCT analysis of femur and tibia in WT, Phospho1-/-, Pit1col2/col2 and [Phospho1-/-; 
Pit1col2/col2] mice at 1 month of age. (A) 3D volume renders of the full samples (side view 
–full leg, front view-tibia, anterior view-femur) 2D orthogonal cross-sections of femurs 
and tibiae. Both 2d volume renders and 3d orthogonal cross-sections show highly bowed/ 
twisted long bones in [Phospho1-/-; Pit1col2/col2] mice compared to WT, Pit1col2/col2 and 
even Phospho1-/- mice. 
!!
Fig. 5: Three-point bending load vs extension graphs on WT (n=6) (A), Phospho1-/-  
(n=4) (B), Pit1col2/col2 (n=7) (C) and [Phospho1-/-; Pit1col2/col2] (n=5) (D) mice femurs. 
Pit1col2/col2 mice show similar break pattern to the WT mice. In contrast, Phospho1-/- mice 
femurs take longer deflection to break and the [Phospho1-/-; Pit1col2/col2] femurs take even 
longer to break. 
 
Fig. 6: Plasma levels of TNAP and PPi. (A) TNAP activity (B) and PPi concentration in 
plasma of 1-month-old mice. TNAP levels were lower and PPi levels were higher in the 
plasma of Pit1col2/col2 and [Phospho1-/-; Pit1col2/col2] mice than in WT and Phospho1-/- mice. 
Data are represented as mean ± SEM, n= 6 mice per group, experiments performed in 
duplicate. 
 
Fig. 7. Determination of percentage of filled MVs and total number of MVs. A) We 
observed a statistically significant decrease in the number of filled MVs in the 
[Phospho1-/-; Pit1col2/col2] samples compared to WT, Phospho1-/- and Pit1col2/col2 samples. 
B) The Phospho1-/- MV preparations show a statistically significant decrease in the total 
number of MVs. The [Phospho1-/-; Pit1col2/col2] MV preparations show a comparable 
decrease in the number of MVs. 
 
Supplemental Fig. 1: MVs were found in chains (A, B) and considered as spheroids with 
the polar diameter (a) as the MV height and the polar diameter (b) as the MV’s width at 
half height (C). 
 
Supplemental Fig. 2: Atomic force microscopy (AFM) of filled (A) and unfilled (B) MVs. 
From left to right: topography, amplitude and three-dimensional reconstruction. AFM 
images were recorded in non-contact (AAC) mode. Height (C) and volume (D) 
distribution for isolated MVs from WT, Phospho1-/-, Pit1flox/flox; Col2a1-cre and 
[Phospho1-/-; Pit1flox/flox; Col2a1-cre] mice.  Peaks were fitted by Gaussian curves. MVs’ 
volumes have been calculated by assuming MVs as spheroidal structures. 
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